Rufinamide: Crystal structure elucidation and solid state characterization
Publication date: 5 February 2018 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 149 Author(s): Nita Salunke, Rajesh Thipparaboina, Rahul B. Chavan, Anurag Lodagekar, Sudhir Mittapalli, Ashwini Nangia, Nalini R. Shastri Rufinamide (R) is a triazole derivative approved for the management of partial seizures and seizures associated with Lennox-Gastaut Syndrome, in November 2007. Crystal structure, solid state characterization, drug-excipient compatibility and solubility play a pivotal role in formulation development. This work deals with the crystal structure elucidation of R by single crystal X-ra...
Source: Journal of Pharmaceutical and Biomedical Analysis - November 8, 2017 Category: Drugs & Pharmacology Source Type: research
The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity
AbstractEpilepsy is common in children and adolescents where its prevalence is 3.2 –5.5/1000. About one-third of patients also have attention deficit hyperactivity/impulsivity disorder (ADHD). The possible relationship between epilepsy and ADHD is still unclear, and ADHD symptoms (such as inattention, hyperactivity, behavioral disturbances) are frequently considered as adverse e ffects of antiepileptic drugs (AEDs). The literature was searched for data on the behavioral effects of AEDs. Phenobarbital is the most frequently reported medication to induce symptoms of ADHD, followed by topiramate and valproic acid. Phenytoi...
Source: Clinical Drug Investigation - October 25, 2017 Category: Drugs & Pharmacology Source Type: research
Real-world data on rufinamide treatment in patients with Lennox –Gastaut syndrome: Results from a European noninterventional registry study
Conclusion The study provided valuable information on LGS and its management, and evidence that rufinamide has a consistent and generally favorable safety/tolerability profile when used in routine clinical practice. ClinicalTrials.Gov identifier NCT01991041 (Source: Epilepsy and Behavior)
Source: Epilepsy and Behavior - September 16, 2017 Category: Neurology Source Type: research
Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
CONCLUSION: The study provided valuable information on LGS and its management, and evidence that rufinamide has a consistent and generally favorable safety/tolerability profile when used in routine clinical practice. CLINICALTRIALS.
GOV IDENTIFIER: NCT01991041.
PMID: 28927712 [PubMed - as supplied by publisher] (Source: Epilepsy and Behaviour)
Source: Epilepsy and Behaviour - September 15, 2017 Category: Neurology Authors: Nikanorova M, Brandt C, Auvin S, McMurray R Tags: Epilepsy Behav Source Type: research
Rufinamide pretreatment attenuates ischemia-reperfusion injury in the gerbil hippocampus.
DISCUSSION: These findings suggest that rufinamide can display neuroprotective effect against cerebral ischemic insults and that its neuroprotective effect may involve the attenuation of ischemia-induced glial activation.
PMID: 28782435 [PubMed - as supplied by publisher] (Source: Neurological Research)
Source: Neurological Research - August 9, 2017 Category: Neurology Tags: Neurol Res Source Type: research
Interactions between cannabidiol and commonly used antiepileptic drugs
This study emphasizes the importance of monitoring serum AED levels and LFTs during treatment with CBD. (Source: Epilepsia)
Source: Epilepsia - July 1, 2017 Category: Neurology Authors: Tyler E. Gaston, E. Martina Bebin, Gary R. Cutter, Yuliang Liu, Jerzy P. Szaflarski, Tags: Full ‐Length Original Research Source Type: research
Assessment of treatment patterns and healthcare costs associated with probable Lennox –Gastaut syndrome
In this study we use a claims-based LGS classifier based on random forest methodology to identify patients with probable LGS from the a Medicaid multi-state database and assess its prevalence across the age spectrum, healthcare utilization, treatment patterns, costs, and comorbid conditions. The classifier identified patients with probable LGS across all ages, with up to 8% of 10-year-old patients with epilepsy identified as having probable LGS. The prevalence of probable LGS was lower in older age cohorts, indicating that it may be under-recognized in older patients. Our analysis showed that probable LGS is associated wit...
Source: Epilepsy and Behavior - June 11, 2017 Category: Neurology Source Type: research
Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome.
In this study we use a claims-based LGS classifier based on random forest methodology to identify patients with probable LGS from the a Medicaid multi-state database and assess its prevalence across the age spectrum, healthcare utilization, treatment patterns, costs, and comorbid conditions. The classifier identified patients with probable LGS across all ages, with up to 8% of 10-year-old patients with epilepsy identified as having probable LGS. The prevalence of probable LGS was lower in older age cohorts, indicating that it may be under-recognized in older patients. Our analysis showed that probable LGS is associated wit...
Source: Epilepsy and Behaviour - June 10, 2017 Category: Neurology Authors: Piña-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J Tags: Epilepsy Behav Source Type: research
Sodium Channel Blockers in the Treatment of Epilepsy
AbstractSodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic –clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic drugs have similar efficacy and share similar dose-dependent, adverse effect profiles, alth ough phenytoin, carbamazepine and oxcarbazepine are more likely to cause idiosyncratic reactions than the others. With the exception of lamotrigine, rufinamide and lacosamide, all are enzyme inducers and most ...
Source: CNS Drugs - May 18, 2017 Category: Neurology Source Type: research
Examining Hospital Utilization and Costs Following Rufinamide Treatment in Children with Intractable Seizures and Developmental Disorders (P3.206)
Conclusions:The results of this retrospective observational study suggest that treatment with rufinamide in children with intractable seizures and developmental disorders can lead to a significant reduction in both hospital utilization and costs.Disclosure: Dr. Li has received personal compensation for activities with Eisai as an employee. Dr. Olhaye has received personal compensation for activities with Eisai Inc. as employee. Dr. Knoth has received personal compensation for activities with Eisai, Inc. as an employee. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Li, X., Olhaye, O., Knoth, R. Tags: Child Neurology I Source Type: research
Hemilability Driven Water Activation: A Ni(II) Catalyst for Base-Free Hydration of Nitriles to Amides.
Abstract
A Ni(II) complex 1 containing pyridyl- and hydroxy-functionalized N-heterocyclic carbenes (NHC) is synthesized and its catalytic utility for selective nitrile hydration to amide under base-free condition is evaluated. The title compound exploits hemilabile pyridyl unit to interact with a catalytically relevant water molecule via hydrogen-bonding and promote nucleophilic water attack to the nitrile. A wide variety of nitriles are hydrated to the corresponding amides including pharmaceutical drugs Rufinamide, Rifater and Piracetam. Synthetically challenging α-hydroxyamides are accessed from cyanohy...
Source: Chemistry - April 7, 2017 Category: Chemistry Authors: Bera JK, Singh K, Sarbajna A, Dutta I, Pandey P Tags: Chemistry Source Type: research
Development and pharmacologic characterization of the rat 6 Hz model of partial seizures
Summary
ObjectiveThe mouse 6 Hz model of psychomotor seizures is a well‐established and commonly used preclinical model for antiseizure drug (ASD) discovery. Despite its widespread use both in the identification and differentiation of novel ASDs in mice, a corresponding assay in rats has not been developed. We established a method for 6 Hz seizure induction in rats, with seizure behaviors similar to those observed in mice including head nod, jaw clonus, and forelimb clonus.
MethodsA convulsive current that elicits these seizure behaviors in 97% of rats (CC97) was determined using a Probit analysis. Numerous prototype ASD...
Source: Epilepsia - April 1, 2017 Category: Neurology Authors: Cameron S. Metcalf, Peter J. West, Kyle E. Thomson, Sharon F. Edwards, Misty D. Smith, H. S. White, Karen S. Wilcox Tags: Full ‐Length Original Research Source Type: research
Do antiepileptic drugs increase the risk of infectious diseases? A meta ‐analysis of placebo‐controlled studies
ConclusionsSome AEDs are associated with a mild increased risk of infection. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - April 1, 2017 Category: Drugs & Pharmacology Authors: Gaetano Zaccara, Fabio Giovannelli, Filippo Sean Giorgi, Valentina Franco, Sara Gasparini, Francesco Mand ò Tacconi Tags: SYSTEMATIC REVIEW AND META ‐ANALYSIS Source Type: research
Lennox –Gastaut Syndrome: A State of the Art Review
Neuropediatrics DOI: 10.1055/s-0037-1601324Lennox–Gastaut syndrome (LGS) is a severe age-dependent epileptic encephalopathy usually with onset between 1 and 8 years of age. Functional neuroimaging studies recently introduced the concept of Lennox–Gastaut as “secondary network epilepsy” resulting from dysfunctions of a complex system involving both cortical and subcortical structures (default-mode network, corticoreticular connections, and thalamus). These dysfunctions are produced by different disorders including hypoxic–ischemic encephalopathies, meningoencephalitis, cortical malformations, neurocutaneous disord...
Source: Neuropediatrics - March 27, 2017 Category: Neurology Authors: Mastrangelo, Mario Tags: Review Article Source Type: research
Dosing considerations for rufinamide in patients with Lennox –Gastaut syndrome: Phase III trial results and real-world clinical data
Conclusions A lower dose and slower titration schedule (“low and slow”) may reduce incidence of AEs without compromising efficacy of rufinamide in LGS. (Source: Seizure)
Source: Seizure - March 8, 2017 Category: Neurology Source Type: research
